Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT04034485 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG: lerodalcibep
DRUG: evolocumab

Sponsor

LIB Therapeutics LLC